- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Durect Corp.
Headquarters: Cupertino, CA, United States
Website: http://www.durect.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: James E. Brown, DVM
Number Of Employees: 31
Enterprise Value: $13,608,000
PE Ratio: -1.26
Exchange/Ticker 1: NASDAQ:DRRX
Exchange/Ticker 2: N/A
Latest Market Cap: $20,124,500
BioCentury | Aug 7, 2024
Management Tracks
Flagship adds White House veteran Panjabi
Plus: Biogen alum Radhakrishnan joins Sofinnova Investments, and updates from Bicycle, iTeos, Fennec, Faron and ORIC
BioCentury | Mar 23, 2023
Management Tracks
New CFOs at Remix, Capstan
Plus: Maderis to be chair at Durect and updates from Generate and Patient Discovery Solutions
BioCentury | Jul 5, 2022
Management Tracks
Health Secretary Javid among ministers quitting U.K. government
Plus Hering made permanent CEO at Adagio and updates from Canbridge, Catalent, Nanoscope, and more
BioCentury | Mar 25, 2022
Management Tracks
Emergent appoints Harsanyi, Katkin in board restructuring
Plus Sosei ratifies executive changes and updates from Mesoblast, Creyon and more
BioCentury | Feb 5, 2021
Product Development
Feb. 5 Quick Takes: FDA approves BMS’s liso-cel; plus AZ’s Imfinzi fails in head and neck cancer trial and updates on Reistone, Spero, Innovent and more
Bristol Myers Squibb Co. (NYSE:BMY) said FDA approved Breyanzi lisocabtagene maraleucel (informally, liso-cel), a CD19-directed CAR T cell therapy to treat adults with relapsed or refractory
BioCentury | Mar 6, 2020
Management Tracks
Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more
BioCentury | Jan 17, 2020
Company News
Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta
BioCentury | Jan 14, 2020
Company News
Amid need for new pain options, FDA panel rebuffs Nektar’s ‘safer’ opioid
BioCentury | Jan 2, 2020
Clinical News
Durect looks ahead to liver indications after Phase IIa miss in psoriasis
BioCentury | Oct 3, 2019
Company News
Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect
Items per page:
1 - 10 of 229